Clinical Trials on HER-2 Positive Metastatic Breast Cancer

Total 2527 results

UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); Syndax Pharmaceuticals

Terminated

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

Breast Cancer | Invasive Breast Cancer | ER-Negative PR-Negative HER2-Negative Breast Cancer

United States
Second Affiliated Hospital, School of Medicine,...
Sun Yat-sen University; Peking University International Hospital; Zhejiang University

Not yet recruiting

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

HER2-positive Breast Cancer | Brain Metastases

China
National Cancer Institute (NCI)

Active, not recruiting

Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

Recurrent Breast Carcinoma | HER2/Neu Positive | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIC Breast Cancer AJCC v7

United States
Pfizer

Completed

Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan

ER/PR(+), Her2(-) Breast Cancer

Taiwan
Shandong Cancer Hospital and Institute

Not yet recruiting

Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

HER2-positive Breast Cancer
Prescient Therapeutics, Ltd.
National Cancer Institute (NCI)

Terminated

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Breast Adenocarcinoma

United States
Korea University Guro Hospital
Korean Cancer Study Group

Active, not recruiting

Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers

Metastatic Cancer | HER2 Gene Mutation

Korea, Republic of
CytomX Therapeutics

Completed

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Neoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 Negative

United States, Spain, Korea, Republic of
University of Washington
National Cancer Institute (NCI)

Completed

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Male Breast Carcinoma

United States
Aarhus University Hospital
Danish Cancer Society

Recruiting

The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity (FEMA)

Metastatic Breast Cancer | Adiposity | Estrogen-receptor-positive Breast Cancer

Denmark
Case Comprehensive Cancer Center

Withdrawn

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer

Stage I Breast Cancer | HER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
George W. Sledge Jr.
National Cancer Institute (NCI)

Completed

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma | Stage III Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Orion Biotechnology Polska Sp. z o.o.

Not yet recruiting

Study of OB-002 in Patients With Refractory Metastatic Cancer

Metastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
Innocrin Pharmaceutical

Completed

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) (CLARITY-01)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the Breast

United States
Baptist Health South Florida
Seagen Inc.

Recruiting

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

HER2-positive Breast Cancer | Brain Metastases

United States
Fudan University

Active, not recruiting

Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases

Breast Cancer | HER2-positive Breast Cancer | Brain Metastases

China
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; Southwest Oncology... and other collaborators

Completed

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

HER2 Positive Breast Carcinoma | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Peru, South Africa
Northwestern University
National Cancer Institute (NCI); MedImmune LLC; Avon Breast Cancer Foundation

Completed

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative

United States
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense

Recruiting

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

Triple Negative Breast Cancer | HER2-positive Breast Cancer | Leptomeningeal Disease

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Recruiting

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

HER2-positive Breast Cancer | Leptomeningeal Disease | Leptomeningeal Metastasis

United States
Williams Cancer Foundation
Syncromune, Inc.

Recruiting

Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors

Cancer | Solid Tumor | Metastatic Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer

Mexico
University of Utah

Completed

Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance (POWER PIINC)

Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | HER2/Neu Negative | Estrogen Receptor and/or Progesterone Receptor Positive

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Breast Adenocarcinoma | Inflammatory Breast Carcinoma

United States
Bolt Biotherapeutics, Inc.
Bristol-Myers Squibb

Recruiting

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

HER2-positive Breast Cancer | HER2-positive Colorectal Cancer | HER2-positive Solid Tumors | HER2-positive Gastroesophageal Cancer | HER2-positive Endometrial Cancer

United States, Spain, France, Korea, Republic of, Italy
Gangnam Severance Hospital
Samsung Medical Center; Asan Medical Center; Severance Hospital

Recruiting

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer (CLEAR)

Breast Cancer | Surgery | Recurrent Breast Cancer | Estrogen Receptor Positive Tumor | Stereotactic Body Radiotherapy | Her2-negative Tumor

Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

HER2/Neu Negative | Stage IV Breast Cancer AJCC v6 and v7 | Estrogen Receptor and/or Progesterone Receptor Positive

United States
Sunnybrook Health Sciences Centre
Harvard University

Unknown

MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative or HER2+ MBC (SYMPToM)

Breast Neoplasm | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Brain Metastases

Canada
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Eisai Inc.

Completed

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Locally Recurrent | Metastatic Breast Cancer ( HER2 Negative)

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | HER2-Positive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
xuexin he

Recruiting

A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone (HER2BAT)

HER2-positive Breast Cancer | Brain Metastases

China
Reva Basho
Merck Sharp & Dohme LLC; Seagen Inc.

Withdrawn

TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases (TOPAZ)

Breast Cancer | HER2-positive Breast Cancer | Brain Metastases | CNS Disease

United States
Istituto Oncologico Veneto IRCCS
Association for Translational Research in Oncology (AS.T.R.O.)

Completed

Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy (PER-ELISA)

Endocrine Sensitive HER2+/HR+ Breast Cancer

Italy
University of Arizona
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
National Cancer Institute (NCI)

Completed

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

Breast Cancer | Breast Neoplasms | Adenocarcinomas | Metastatic Solid Tumors Characterized by HER2/Neu Expression

United States
Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Unknown

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

China
OncoSec Medical Incorporated

Completed

Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC (TNBC)

ER-Negative PR-Negative HER2-Negative Breast Cancer

United States
Molecular Templates, Inc.

Terminated

Study of MT-5111 in HER2-positive Solid Tumors (MT-5111)

HER2-positive Solid Cancers

United States, Australia, New Zealand
Novartis Pharmaceuticals

Completed

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

Advanced HER2-positive Breast Cancer or Gastric Cancer

Taiwan, Netherlands, Italy, United States, Belgium, United Kingdom, Korea, Republic of, France, Spain
Celularity Incorporated

Active, not recruiting

CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Metastatic HER2 Positive Gastroesophageal Junction Cancer

United States
NKGen Biotech, Inc.

Withdrawn

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Sarcoma | Cervical Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | EGF-R Positive Non-Small... and other conditions
ECOG-ACRIN Cancer Research Group

Recruiting

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Invasive Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
Samsung Medical Center

Completed

Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer

HER2-positive Refractory Advanced Cancer

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | Progesterone Receptor Positive | Postmenopausal | KIT Positive | PDGFR Positive

United States
BriaCell Therapeutics Corporation

Recruiting

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (BRIA-ABC)

Breast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage Cancer

United States

Clinical Trials on HER-2 Positive Metastatic Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations